BETH LABSON FREEMAN, District Judge.
Plaintiffs bring this indirect purchaser class action against four manufacturers of titanium dioxide, asserting claims under state and federal antitrust laws, state consumer protection statutes, and state common laws. Defendants move to dismiss for lack of Article III standing, lack of antitrust standing, and failure to state a claim upon which relief may be granted. The Court has considered the briefing and the oral argument presented at the hearing on July 10, 2014. For the reasons discussed below, the motion is GRANTED IN PART, with leave to amend.
Defendants E.I. DuPont de Nemours and Company ("DuPont"), Huntsman International, LLC ("Huntsman"), Kronos Worldwide, Inc. ("Kronos"), and Millennium Inorganic Chemicals, Inc. ("Millennium") manufacture and sell titanium dioxide, a chemical that is used as an ingredient in numerous products including paint, paper, plastic, inks, pharmaceutical coatings, toothpaste, sunscreen, cosmetics, food, rubber, and ceramic. Titanium dioxide is unique in that it "traps and reflects light better than almost any known substance." First Am'd Compl. ¶ 49. There are no competitive substitutes for titanium dioxide in consumer products.
In 2010, direct purchasers of titanium dioxide filed a putative class action against DuPont, Huntsman, Kronos, and Millennium in the District of Maryland, alleging a price-fixing conspiracy in violation of antitrust and consumer protection laws. See Case No. 1:10-cv-00318. Following significant motion practice, that case was set for a four-week jury trial to commence in September 2013. The parties settled on the eve of trial, and on December 13, 2013 the court approved the class action settlement and entered judgment.
While the direct purchaser action was pending, the present indirect purchaser action was filed by seven paint retailers: Los Gatos Mercantile, Inc. dba Los Gatos Ace Hardware; Fred Swaim, Inc. dba Quality Auto Parts; Ace Hardware of South Walton, Inc.; Lexington Home Center, LLC; R.F. Cole, Inc. dba Brewers Paint Center; Cusimano Carstar Collision, Inc.; and The Carpetshoppe, Inc. Plaintiffs subsequently filed the operative first amended complaint ("FAC") adding two individual plaintiffs, Morgan Tanner and William Aviles.
The FAC alleges the following facts: Defendants and their co-conspirators engaged in collusive pricing to dominate and control the titanium dioxide market in the United States. Titanium dioxide is particularly susceptible to collusive pricing because demand is inelastic and the titanium dioxide industry has high barriers to entry. Defendants and their co-conspirators took advantage of those circumstances by discussing pricing when they met at various trade association functions and then engaging in lock-step price increases. The coordinated price increases occurred from 2002 through 2008 despite flat demand and excess supply.
The overcharges for titanium dioxide were passed through each level of distribution between Defendants and Plaintiffs, who purchased "paint and other products containing Titanium Dioxide manufactured by one or more of the Defendants." FAC ¶¶ 15-21. Titanium dioxide can be physically traced through the chain of distribution, as can the overcharges. Id. ¶ 143. Defendants concealed their collusive activities by releasing public statements indicating that price increases were the result of competitive factors. Plaintiffs were not on inquiry notice of the price-fixing conspiracy until after July 2010, when direct purchasers such as Sherwin-Williams publicly announced that they were passing on titanium dioxide price increases to indirect purchasers.
Based upon these allegations, Plaintiffs assert claims on behalf of several putative classes that purchased "products" containing "in some form" titanium dioxide manufactured by one or more of the Defendants or co-conspirators. FAC ¶¶ 35-38. The class period is defined as "the period from and including January 1, 2002 through such time as the anticompetitive effects of Defendants' conduct ceased." Id. ¶ 6. The proposed classes include a Nationwide Class seeking injunctive and equitable relief; a Merchant Class comprising business entities doing business in "Merchant States" that bought products containing titanium dioxide for resale; a Consumer Class comprising individuals living in "Consumer States" who bought products containing titanium dioxide for personal use and not for resale; and a Commercial End User Class comprising individuals living in "Commercial End User States" who bought products containing titanium dioxide for personal use and not for resale. Id. ¶¶ 35-38.
The operative FAC asserts claims for: (1) damages under antitrust laws of twenty-five states; (2) damages under consumer protection laws of thirteen states; (3) disgorgement under unjust enrichment laws of thirty-two states; and (4) injunctive and equitable relief under the Sherman Act, 15 U.S.C. § 1. Defendants seek dismissal of all claims for lack of Article III standing, lack of antitrust standing, and failure to state a claim upon which relief may be granted.
A motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(1)
Defendants contend that Plaintiffs lack Article III standing to assert claims under the laws of states in which no Plaintiff resides or has purchased products.
Surprisingly, there is no controlling case law on this issue. The Ninth Circuit has indicated that in at least some circumstances, Article III issues properly are considered before class certification. In Easter v. Am. West Fin., 381 F.3d 948 (9th Cir. 2004), borrowers filed a class action in state court against mortgage loan originators, assignees, and others, alleging violations of Washington state laws in connection with certain mortgage loans. The loans in question were sold to various investment trusts ("trust defendants") that pooled the loans together, securitized the loans into trusts, and sold interests in the trusts to investors. Id. at 954. The Ninth Circuit held that the borrowers lacked Article III standing to sue trust defendants who did not hold a named plaintiff's note, observing that "[t]o satisfy the traceability requirement, a class action plaintiff must `allege a distinct and palpable injury to himself, even if it is an injury shared by a large class of other possible litigants.'" Id. at 961 (quoting Warth v. Seldin, 422 U.S. 490, 501 (1975)). As relevant here, the court concluded that "[t]he district court correctly addressed the issue of standing before it addressed the issue of class certification." Id. at 962.
The trend in the Northern District of California is to consider Article III issues at the pleading stage in antitrust cases and to dismiss claims asserted under the laws of states in which no plaintiff resides or has purchased products. For example, In re Ditropan XL Antitrust Litig., 529 F.Supp.2d 1098 (N.D. Cal. 2007) addressed indirect purchaser claims asserted against a drug manufacturer. Concluding that "at least one named plaintiff must have standing with respect to each claim the class representatives seek to bring," the district court dismissed all claims based upon the laws of states in which no named plaintiff resided. Id. at 1107. The court expressly rejected the plaintiffs' argument that determination of standing was premature prior to class certification. Id.
Most courts in this district have followed Ditropan's lead. See, e.g., In re Optical Disk Drive Antitrust Litig., No. 3:10-md-2143 RS, 2011 WL 3894376, at *13 (N.D. Cal. Aug. 3, 2011) ("Defendants have adequately shown that dismissal of state law claims is appropriate with respect to those jurisdictions in which none of the named class representatives reside, notwithstanding plaintiffs' arguments that it would not contravene standing requirements to allow those claims to proceed."); Pecover v. Electronics Arts Inc., 633 F.Supp.2d 976, 984-85 (N.D. Cal. 2009) (dismissing claims under laws of states in which named plaintiffs did not purchase products); In re Apple & AT & TM Antitrust Litig., 596 F.Supp.2d 1288, 1309 (N.D. Cal. 2008) (dismissing claims asserted under laws of forty states in which no named plaintiff resided); In re Graphics Processing Units Antitrust Litig. ("GPU I"), 527 F.Supp.2d 1011, 1026-27 (N.D. Cal. 2007) ("no named plaintiff has standing to bring antitrust claims in those states [where no plaintiff resides], and defendants' motion to dismiss those claims will be GRANTED"); but cf. In re Actimmune Mktg. Litig.,
Courts outside the district likewise have dismissed claims asserted under the laws of states in which no named plaintiff resides or has purchased products. See, e.g., In re Niaspan Antitrust Litig., ___ F.Supp.2d ___, 2014 WL 4403848, at *16 (E.D. Pa. Sept. 5, 2014) ("Because standing must be resolved on a claim-by-claim basis, the Court agrees with defendants that the named plaintiffs lack standing to assert claims under the laws of the states in which they do not reside or in which they suffered no injury."); In re Packaged Ice Antitrust Litig., 779 F.Supp.2d 642, 658 (E.D. Mich. 2011) (same).
However, a number of district courts have reached contrary holdings. For example, In re Hydroxycut Mktg. and Sales Practices Litig., 801 F.Supp.2d 993 (S.D. Cal. 2011) addressed class claims asserted by consumers of a weight loss supplement under various state consumer protection and unfair trade practices laws. Opining that "[t]he constitutional issue of standing should not be conflated with Rule 23 class action requirements," the court held that the relevant question was "not whether Named Plaintiffs have standing to sue Defendants — they most certainly do — but whether their injuries are sufficiently similar to those of the purported Class to justify the prosecution of a nationwide class action." Id. at 1005 (internal quotation marks and citation omitted). The court denied the defendants' motion to dismiss claims brought under the laws of states in which the named plaintiffs did not reside. Id.
Several other courts have articulated similar rationales. See, e.g., In re Processed Egg Prods. Antitrust Litig., 851 F.Supp.2d 867, 886-87 (E.D. Penn. 2012) (holding that it was irrelevant for Article III purposes whether the named plaintiffs were within the zone of persons protected by the state statutes at issue, that is, whether they had statutory standing); In re Bayer Corp. Combination Aspirin Prods. Mktg. and Sales Practices Litig., 701 F.Supp.2d 356, 377 (E.D.N.Y. 2010) ("Whether the named plaintiffs have standing to bring suit under each of the state laws alleged is immaterial because they are not bringing those claims on their own behalf, but are only seeking to represent other, similarly situated consumers in those states.") (internal quotation marks and citation omitted); Jepson v. Ticor Title Ins. Co., No. C06-1723-JCC, 2007 WL 2060856, at *1-2 (W.D. Wash. May 1, 2007) (holding that class certification is "logically antecedent" to Article III concerns when the named plaintiff has alleged injury flowing from the defendant's conduct and the only issue is whether the named plaintiff should be permitted to represent "a class of those similarly injured by this Defendant under analogous laws in other states").
After careful consideration, this Court joins the majority of courts in the Northern District in concluding that dismissal is appropriate with respect to claims asserted under the laws of states in which no Plaintiff resides or has purchased products.
Accordingly, Defendants' motion is GRANTED with leave to amend as to claims asserted under the law of states other than Arkansas, California, Florida, Mississippi, New York, South Carolina, and Tennessee.
With respect to antitrust claims brought under federal statute, the presiding court must determine "whether the plaintiff is a proper party to bring a private antitrust action." Assoc. Gen. Contractors v. Cal. State Council of Carpenters ("AGC"), 459 U.S. 519, 535 n.31 (1983). "The label `antitrust standing' has traditionally been applied to some of the elements of this inquiry." Id. "Under AGC, courts consider (1) the nature of plaintiffs' injuries and whether plaintiffs were participants in the relevant markets; (2) the directness of the alleged injury; (3) the speculative nature of the alleged harm; (4) the risk of duplicative recovery; and (5) the complexity in apportioning damages." In re: TFT-LCD (Flat Panel) Antitrust Litig., 586 F.Supp.2d 1109, 1123 (N.D. Cal. 2008) (citing AGC, 459 U.S. at 536-39).
A challenge to antitrust standing properly is brought under Federal Rule of Civil Procedure 12(b)(6). See Knevelbaard Dairies v. Kraft Foods, Inc., 232 F.3d 979, 989 (9th Cir. 2000) (analyzing AGC factors in the context of a Rule 12(b)(6) motion); see also Brantley v. NBC Universal, Inc., 675 F.3d 1192, 1197 (9th Cir. 2012) (characterizing "antitrust standing" as a pleading requirement for a Sherman Act § 1 claim). A Rule 12(b)(6) motion "tests the legal sufficiency of a claim." Conservation Force v. Salazar, 646 F.3d 1240, 1241-42 (9th Cir. 2011) (internal quotation marks and citation omitted). While a complaint need not contain detailed factual allegations, it "must contain sufficient factual matter, accepted as true, to `state a claim to relief that is plausible on its face.'" Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). A claim is facially plausible when it "allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Id.
Defendants contend that the AGC factors apply to Plaintiffs' state law antitrust claims as well as their Sherman Act § 1 claim. There is no dispute that the Sherman Act § 1 claim is subject to an AGC analysis. However, because damages are not available under a § 1 claim, the fourth factor (risk of duplicative recovery) and fifth factor (complexity in apportioning damages) do not apply. See In re Plasma-Derivative Protein Therapies Antitrust Litig., No. MDL 2109, 09 C 7666, 2012 WL 39766, at *9 (N.D. Ill. Jan. 9, 2012). At the hearing, Defendants' counsel agreed that with respect to the Sherman Act § 1 claim, the appropriate test is "AGC lite."
However, the parties disagree whether AGC applies to Plaintiffs' state law antitrust claims. Plaintiffs contend that it does not, arguing that such application would effectively abrogate the remedies authorized by the relevant states' repealer statutes.
Plaintiffs assert claims under the antitrust laws of twenty-five states but they are residents of just four: California, Mississippi, New York, and Tennessee. Because Plaintiffs lack Article III standing to pursue claims under the laws of states in which no Plaintiff resides or purchased products, the Court's AGC analysis is limited to the antitrust laws of those four states.
Federal courts have adopted different criteria for determining whether the AGC factors apply to a particular state's antitrust statute. In Knevelbaard, the Ninth Circuit simply announced that California's Cartwright Act is subject to the AGC factors. Knevelbaard, 232 F.3d at 987. At least one district court also has applied AGC to Cartwright Act claims, relying on Knevelbaard. See In re Dynamic Random Access Memory (DRAM) Antitrust Litig. ("DRAM I"), 516 F.Supp.2d 1072, 1088 (N.D. Cal. 2007). DRAM I also held that AGC applies to the antitrust statutes of thirteen other states based upon state court decisions applying federal law and/or statutory harmonization provisions indicating that federal law applies. Id. at 1093-95.
A narrower approach was articulated in the decision In re Graphics Processing Units Antitrust Litig. ("GPU II"), 540 F.Supp.2d 1085 (N.D. Cal. 2007). In GPU II, the court determined that application of the AGC factors is appropriate when a state's highest court has expressly endorsed AGC; may or may not be appropriate when AGC has been endorsed only by an intermediate appellate court; and is not appropriate when the only basis for applying AGC is a harmonization provision in the state antitrust statute. Id. at 1097. Unlike DRAM I, which applied AGC to California's Cartwright Act, GPU II concluded that AGC may or may not apply to the Cartwright Act. Id.
Flat Panel adopted yet a narrower approach, holding that "it is inappropriate to broadly apply the AGC test to plaintiffs' claims under the repealer states' laws in the absence of a clear directive from those states' legislatures or highest courts." Flat Panel, 586 F. Supp. 2d at 1123.
This Court concludes that it is appropriate to apply the AGC factors to a repealer statute if the state legislature or a state court decision clearly indicates that federal law should be followed in construing the statute. A decision of the state's highest court is controlling, and a lower state court is in a better position than this Court to predict its highest court's approach.
Turning to the states at issue here, at least one intermediate appellate court has applied AGC to California's Cartwright Act. See Vinci v. Waste Mgmt., Inc., 36 Cal.App.4th 1811, 1814 (1995). The Ninth Circuit has done so as well, as discussed above. See Knevelbaard, 232 F.3d at 987. At least one state court decision has applied AGC to New York's antitrust statute. See Ho v. Visa U.S.A. Inc., No. 112316/00, 2004 WL 1118534, at *2-3 (N.Y. Sup. Ct. Apr. 21, 2004), aff'd 16 A.D.3d 256 (N.Y. App. Div. 2005). Accordingly, this Court concludes that application of the AGC factors is appropriate with respect to claims asserted under California and New York antitrust law.
There do not appear to be any state court decisions applying AGC to the antitrust statutes of Mississippi, see DRAM I, 516 F. Supp. 2d at 1095, or Tennessee.
Applying the AGC factors to the Sherman Act § 1 claim and the claims brought under the antitrust laws of California and New York, the Court concludes that Plaintiffs have failed to plead facts establishing antitrust standing.
With respect to the first factor — the nature of the plaintiffs' injuries and whether the plaintiffs were participants in the relevant markets — courts have adopted different approaches to the definition of the relevant market. In DRAM I, the plaintiffs alleged that the defendants fixed prices for dynamic random access memory ("DRAM"), a type of semiconductor chip used in computers and other consumer electronics. See DRAM I, 516 F. Supp. 2d at 1082. Plaintiffs brought an indirect purchaser lawsuit alleging that they paid artificially high prices for electronic goods that incorporated DRAM. The court found that "plaintiffs who are purchasing products in which DRAM is a component, rather than DRAM itself, are participating in a secondary market that is incidental to the primary price-fixed market (i.e., the market for DRAM modules themselves)." Id. at 1091. Following amendment of the complaint to allege that the DRAM and computer markets were "inextricably linked," the court dismissed the plaintiffs' state antitrust claims on the ground that the new allegation was insufficient to establish that the plaintiffs were participating in the same market as the allegedly restrained DRAM market. See In re Dynamic Random Access Memory (DRAM) Antitrust Litig. ("DRAM II"), 536 F.Supp.2d 1129, 1140-41 (N.D. Cal. 2008).
However, Flat Panel reached a different result on similar facts. In that case, the indirect purchaser plaintiffs alleged price-fixing with respect to LCD panels, and claimed that they paid artificially high prices for products such as computer monitors, laptop computers, and televisions that incorporated LCD panels. See Flat Panel, 586 F. Supp. 2d at 1114. The plaintiffs made the same "inextricably linked" allegation that was rejected in DRAM II. The court in Flat Panel found the allegation to be sufficient for pleading purposes, holding that it was not clear as a factual matter whether the plaintiffs and defendants were participating in the same market or in analytically distinct markets but that the issue should be resolved on a more developed record. Flat Panel, 586 F. Supp. 2d at 1123. The court also observed that "even if plaintiffs are not participants in the relevant market, they have also alleged that TFT-LCD panels are identifiable, discrete physical objects that do not change form or become an indistinguishable part of the TVs, computer monitors, laptops, or other products in which they are contained, and [t]hus LCD panels follow a traceable physical chain from the defendants to the OEMs to the purchasers of the finished products incorporating LCD panels." Id. (internal quotation marks and citation omitted) (alteration in the original). The court suggested that these allegations were sufficient to satisfy the first factor of AGC. Id.; accord, GPU II, 540 F. Supp. 2d at 1098 (finding that first factor "slightly favor[ed] standing" because graphics processing units — GPUs — were separate components of a computer and that costs attributable to GPUs were traceable through the chain of distribution).
In the present case, Plaintiffs have defined the relevant market to include every product in the United States that contains titanium dioxide. A market that includes such a broad array of products cannot be considered the same market as the allegedly restrained market for titanium dioxide itself. As noted above, that would be the end of the analysis under DRAM I and DRAM II. Even if the Court were to apply the reasoning of Flat Panel and GPU II, Plaintiffs have failed to allege facts showing that the market for every product containing titanium dioxide — even in mere trace amounts — is "inextricably linked" to the titanium dioxide market. Moreover, both Flat Panel and GPU II turned in part upon allegations that the allegedly price-fixed products — LCD panels and GPUs, respectively — could be physically traced through the distribution chain because they were identifiable, discrete components that did not become indistinguishable parts of the finished consumer end product. In the present case, however, the allegedly price-fixed product is a chemical ingredient that does become an indistinguishable part of the finished consumer product. Thus although Plaintiffs allege that they will be able to physically trace titanium dioxide manufactured by Defendants through the distribution chain, that allegation is implausible given the breadth of the defined market and the manner in which titanium dioxide is incorporated into finished consumer products.
In a similar case involving alleged price-fixing of an ingredient, the court concluded that purchasers of products containing potash, a combination of mineral and chemical salts, "failed to show they are participants in the relevant market, and, as a result, have not satisfied the antitrust injury requirement." In re Potash Antitrust Litig., 667 F.Supp.2d 907, 940 (N.D. Ill. 2009), vacated and remanded on other grounds by Minn-Chem, Inc. v. Agrium Inc., 657 F.3d 650 (7th Cir. 2011), aff'd Minn-Chem, Inc. v. Agrium, Inc., 683 F.3d 845 (7th Cir. 2012). This Court need not decide at this time whether tracing ever would be possible with respect to a chemical ingredient such as titanium dioxide; it is clear that Plaintiffs have not alleged the necessary facts here.
With respect to the second and third AGC factors — the directness of the alleged injury and the speculative nature of the alleged harm — Plaintiffs allege the following facts: Defendants conspired to and did fix the price of titanium dioxide at artificially high levels throughout the United States; as a result, direct purchasers paid unfairly high prices for titanium dioxide; those overcharges were passed through each level of distribution as titanium dioxide was incorporated into consumer products; and Plaintiffs and class members paid supracompetitive prices for products containing titanium dioxide during the class period. FAC ¶¶ 141-142. Plaintiffs assert that a regression analysis may be used to determine the impact of the increase in the price of titanium dioxide on products containing titanium dioxide while controlling for other factors that impact the price of those products. FAC ¶ 146.
These allegations are insufficient given the absence of any facts indicating how the alleged overcharges for titanium dioxide could be traced through the hundreds or perhaps thousands of distribution chains implicated by the breadth of Plaintiffs' market definition. Moreover, with respect to consumer products far down the distribution chain and products that do not contain significant amounts of titanium dioxide, the alleged injury appears to be too remote. When asked about the breadth of the market definition at the hearing, Plaintiffs' counsel acknowledged that the market would have to be narrowed at some point. However, counsel suggested that the Court focus solely on the allegations regarding paint in analyzing the motion to dismiss, and he argued that with respect to paint traceability has been fairly alleged for antitrust standing. The problem with that argument is that the FAC clearly is not limited to paint, and the Court must evaluate the FAC as it is presently framed.
The fourth and fifth factors — a risk of duplicative recovery and the complexity in apportioning damages — are not implicated with respect to the Sherman Act § 1 claim. With respect to the state law claims, Plaintiffs have not explained adequately how they intend to avoid duplicative recovery given that the putative classes include every level of the distribution chain. Moreover, in light of the fact that the defined market runs the spectrum between products containing significant amounts of titanium dioxide to products containing only trace amounts, the Court fails to see how apportionment of damages could be anything other than complex.
Plaintiffs may be able to cure these defects by alleging a more limited market of products containing titanium dioxide; showing how that market (whatever it is) is "inextricably linked" to the primary, restrained market; and alleging facts demonstrating that titanium dioxide can be traced through the distribution chain. However, because of the way that Plaintiffs' claims currently are framed, the motion to dismiss for lack of antitrust standing is GRANTED with leave to amend as to the Sherman Act § 1 claim and the claims asserted under California and New York state antitrust law. The motion to dismiss for lack of antitrust standing is DENIED with respect to the claims asserted under Mississippi and Tennessee state antitrust law, as AGC does not apply to those claims.
Plaintiffs allege that Defendants' conduct gives rise to liability under consumer protection statutes of thirteen states. Plaintiffs reside in only five of those states: Arkansas, California, Florida, New York, and South Carolina.
It is unclear whether price-fixing claims may be asserted under the Arkansas Deceptive Trades Practices Act ("ADTPA"), Ark. Code Ann. § 4-88-101 et seq. "[T]he ADTPA protects consumers from unfair ways of doing business." Indep. Cnty. v. Pfizer, Inc., 534 F.Supp.2d 882, 887 (E.D. Ark. 2008). At least one Arkansas court has held that price-fixing is actionable under the ADTPA as an "unconscionable, false or a deceptive act." Burton v. Micron Tech., Inc., No. CV 2004-226-1, at 2 (Ark. Cir. Ct. 1st Div. Nov. 6, 2009) (provided at Pl.'s Exh. G). District courts have split on the issue. DRAM I held that price fixing claims are permitted under the ADTPA, see DRAM I, 516 F. Supp. 2d at 1108-09, while Flat Panel and GPU I held that they are not, see Flat Panel, 586 F. Supp. 2d at 1125; GPU I, 527 F. Supp. 2d at 1029-30. In Flat Panel, the court's ruling turned upon the plaintiffs' failure to cite any Arkansas authority construing the ADTPA to encompass price-fixing claims; the court was "unwilling to expansively interpret the statute" absent such authority. Flat Panel, 586 F. Supp. 2d at 1125. In GPU I, the court simply concluded that price-fixing "is not the kind of conduct prohibited" under the statute. GPU I, 527 F. Supp. 2d at 1030.
Even assuming that a price-fixing claim may be asserted under the ADTPA, "Arkansas law recognizes the remoteness doctrine" such that a consumer claim is subject to dismissal if there is no direct link between the alleged misconduct and the claimed damages. Indep. Cnty., 534 F. Supp. 2d at 888-89. As discussed above in connection with antitrust standing, Plaintiffs have not alleged facts showing that there is a direct connection between the alleged price-fixing of titanium dioxide and any damages suffered as a result of Plaintiffs' purchase of products containing titanium dioxide. Accordingly, the motion to dismiss is GRANTED with leave to amend as to the claim brought under the ADTPA.
California's Unfair Competition Law ("UCL") provides a vehicle for recovery against a defendant engaged in an "unlawful, unfair or fraudulent business act or practice." Cal. Bus. & Prof. Code § 17200. "The broad scope of the statute encompasses both anticompetitive business practices and practices injurious to consumers." Chavez v. Whirlpool Corp., 93 Cal.App.4th 363, 374 (2001). However, "[i]f the same conduct is alleged to be both an antitrust violation and an `unfair' business act or practice for the same reason — because it unreasonably restrains competition and harms consumers — the determination that the conduct is not an unreasonable restraint of trade necessarily implies that the conduct is not `unfair' toward consumers." Id. Because Plaintiffs have failed to state a claim for an antitrust violation, they have failed to state a claim under the UCL based upon the alleged anticompetitive conduct. See LiveUniverse, Inc. v. MySpace, Inc., 304 Fed. Appx. 554, 558 (9th Cir. 2008) ("Because LiveUniverse fails to state a claim under the Sherman Act, it also fails to state a claim under § 17200."). Accordingly, the motion to dismiss is GRANTED with leave to amend as to the claim brought under § 17200.
The Florida Deceptive and Unfair Trade Practices Act ("DTPA") prohibits "[u]nfair methods of competition, unconscionable acts or practices, and unfair or deceptive acts or practices in the conduct of any trade or commerce." Fla. Stat. § 501.204(1). "[T]he Florida DTPA clearly expresses the legislative policy to authorize consumers (that is, indirect purchasers) to bring actions under the Florida DTPA for price-fixing conduct." Mack v. Bristol-Myers Squibb Co., 673 So.2d 100, 109 (Fla. App. 1 Dist. 1996). However, as discussed above, Plaintiffs have not alleged facts sufficient to show that they suffered any injury as a result of the alleged price fixing. Accordingly, the motion to dismiss is GRANTED with leave to amend as to the claim brought under the Florida DTPA.
New York's consumer protection law provides that "[d]eceptive acts or practices in the conduct of any business, trade or commerce or in the furnishing of any service in this state are hereby declared unlawful." N.Y. Gen. Bus. Law § 349(a). "In order to state a claim under section 349, plaintiffs must allege first, that the challenged act or practice was consumer-oriented; second, that it was misleading in a material way; and third, that the plaintiff suffered injury as a result of the deceptive act." DRAM II, 536 F. Supp. 2d at 1143 (internal quotation marks and citation omitted). Defendants argue that Plaintiffs' claims do not meet the "consumer-oriented" requirement because Plaintiffs allege price-fixing agreements between companies, and not conduct aimed specifically at New York consumers. That argument was expressly rejected in DRAM II. However, even if the Court were to adopt DRAM II's holding on that point, Plaintiffs have failed to allege facts showing that they suffered injury as a result of the alleged price-fixing. Accordingly, the motion to dismiss is GRANTED with leave to amend as to the claim brought under New York's consumer protection law.
The South Carolina consumer protection law provides that: "Any person who suffers any ascertainable loss of money or property, real or personal, as a result of the use or employment by another person of an unfair or deceptive method, act or practice declared unlawful by § 39-5-20 may bring an action individually, but not in a representative capacity, to recover actual damages." S.C. Code § 39-5-140(a). Despite the express language limiting suits to individual actions, at least some district courts have held that consumer class actions may be brought under this statute in federal court. See, e.g., In re Hydroxycut Mktg. and Sales Practices Litig., 299 F.R.D. 648, 652 (S.D. Cal. 2014) (holding that statutory provisions prohibiting class actions for unfair or deceptive practices are procedural rather than substantive, and that the viability of class actions under the statute is governed by Federal Rule of Civil Procedure 23). However, even assuming that a class action is viable under South Carolina's consumer protection law, the claim fails to allege that Plaintiffs suffered an ascertainable loss "as a result" of Defendants' alleged unfair price-fixing practices. Accordingly, the motion to dismiss is GRANTED with leave to amend as to the claim brought under South Carolina's consumer protection law.
Plaintiffs assert unjust enrichment claims under the laws of "all states" alleged in Claims 1 and 2. No further specificity is provided in the FAC; it does not identify the relevant laws of the thirty-two states in question or attempt to set forth facts showing that claims lie under each of those laws. The Court informed counsel at the hearing that those allegations are inadequate and that Plaintiffs must identify and plead the elements of unjust enrichment for each state. Accordingly, the motion is GRANTED with leave to amend as to Claim 3.
Defendants contend that certain of Plaintiffs' state law antitrust and consumer protection claims are time-barred under applicable limitations periods. At the hearing, the Court expressed reservations regarding the timeliness of Plaintiffs' claims and their allegations of delayed discovery. Plaintiffs' counsel indicated that Plaintiffs wish to amend their delayed discovery allegations to set forth additional facts and a different discovery date. Plaintiffs are given leave to do so.
For the foregoing reasons, IT IS HEREBY ORDERED that: